Abound Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Abound Wealth Management
- $271 Billion
- Q2 2024
A detailed history of Abound Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 12 shares of CPRX stock, worth $245. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12
Previous 17
29.41%
Holding current value
$245
Previous $271,000
31.37%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$382 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$186 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$123 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$61.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.1B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...